Omnicell Shares Surge 21% Following Q1 Earnings Beat and Raised Guidance

Omnicell (NASDAQ: OMCL) saw its shares jump nearly 21% on Tuesday after delivering a first-quarter performance that significantly outperformed market expectations. The healthcare technology provider reported robust growth in both revenue and profitability, driven by strong execution across its core business segments. The results highlight a growing demand for automated medication management and connected device portfolios within hospitals and pharmacies. By optimizing point-of-care solutions, Omnicell has managed to scale its operations more efficiently than analysts had previously projected. Quarterly revenue rose approximately 15% year-over-year to just under $310 million, surpassing the consensus estimate of $304 million. Product revenue led the growth, increasing 20% to nearly $175 million, while service revenue grew 8% to $135 million. Non-GAAP net income saw a dramatic increase, rising to $25 million ($0.55 per share) from $12 million in the prior year, beating the expected $0.33 per share. Looking ahead, management raised its 2026 non-GAAP net income per share forecast to a range of $1.80 to $2.00. Full-year revenue is projected to land between $1.22 billion and $1.26 billion. The positive guidance suggests a sustainable trajectory for the company's efficiency-driven product suite as healthcare providers continue to seek operational optimizations.